SuperworthAbbott Laboratories EPS ABT
Diluted earnings per share by quarter and over the last twelve months, from 1995.
- Last 12 months, to Sep 30, 2026
- $2.68
- Latest quarter, Q3 FY26
- $0.53
- −44% on a year earlier
- Fiscal year 2025
- $3.72
- −51% on the year before
Abbott Laboratories' earnings per share was $2.68 over the twelve months to Sep 30, 2026, down 66% on a year earlier.
In its latest quarter, Q3 FY26, it was $0.53, down 44% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 8% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $3.72 | −51% |
| FY2024 | $7.65 | +135% |
| FY2023 | $3.26 | −17% |
| FY2022 | $3.91 | −1% |
| FY2021 | $3.94 | +58% |
| FY2020 | $2.50 | +21% |
| FY2019 | $2.06 | +55% |
| FY2018 | $1.33 | +412% |
| FY2017 | $0.26 | −72% |
| FY2016 | $0.93 | −68% |
| FY2015 | $2.92 | +96% |
| FY2014 | $1.49 | −8% |
| FY2013 | $1.62 | −57% |
| FY2012 | $3.73 | +24% |
| FY2011 | $3.00 | +1% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $0.53 | −44% | $2.68 | |
| Q2 FY26 | $0.53 | −48% | $3.09 | |
| Q1 FY26 | $0.61 | −20% | $3.57 | |
| Q4 FY25 | $1.01 | −81% | $3.72 | |
| Q3 FY25 | $0.94 | +0% | $7.98 | |
| Q2 FY25 | $1.01 | +36% | $7.98 | |
| Q1 FY25 | $0.76 | +9% | $7.71 | |
| Q4 FY24 | $5.27 | +479% | $7.65 | |
| Q3 FY24 | $0.94 | +15% | $3.29 | |
| Q2 FY24 | $0.74 | −5% | $3.17 | |
| Q1 FY24 | $0.70 | −7% | $3.21 | |
| Q4 FY23 | $0.91 | +54% | $3.26 |
Against its peers
Companies in Medical - Devices nearest Abbott Laboratories' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ABTAbbott Laboratories | $2.68 | −66% a year |
| MDTMedtronic | $4.07 | +12% a year |
| SYKStryker | $9.65 | +28% a year |
| BSXBoston Scientific | $2.47 | +47% a year |
| EWEdwards Lifesciences | $1.74 | −75% a year |
| GEHCGE HealthCare Technologies | $4.36 | −11% a year |
| DXCMDexCom | $2.52 | +76% a year |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| Peer median | $4.07 |
Where Abbott Laboratories ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Abbott Laboratories
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.